31 March 2021: We integrated content from the NHS England specialty guide on rheumatology during the coronavirus pandemic into this guideline. This includes information on making treatment decisions based on the person's condition and their medicines, advice on shielding and self-isolation and recommendations on organising services based on COVID-19 prevalence.
2 July 2020: We added a bullet point to recommendation 3.2 to highlight the possible risk of adrenal crisis for patients on long-term corticosteroids.
21 May 2020: We added a link from recommendation 3.2 to the advice in NICE's COVID-19 rapid guideline: children and young people who are immunocompromised on factors to take into account when considering temporarily stopping some drugs. We aligned recommendation 1.4 with current government advice on social distancing.
30 April 2020: We added information to recommendation 3.2 to highlight that the half-life of some drugs means that immunosuppression will continue for some time after stopping treatment.
24 April 2020: We amended recommendation 4.9 to include switching from an intravenous treatment to a subcutaneous form of the same treatment. Subcutaneous infliximab is now available, so we deleted a recommendation on switching from infliximab to a different treatment in subcutaneous form.
Minor changes since publication
22 July 2021: We made it clear what the information in tables 1 and 2 was based on.
21 December 2020: In recommendation 4.11 we removed a link to an NHS specialty guide that has been withdrawn.
3 June 2020: We updated the link in recommendation 6.6 to cover NHS England's specialty guides for adults and children.